China Haidebao program

Grand Pharma (China Grand Pharmaceutical and Healthcare Holdings) is a leading international pharmaceutical company based in China, specializing in innovative drugs, medical devices, and biotechnology. The company has established a comprehensive portfolio across oncology, cardiovascular intervention, respiratory health, and anti-infection. A key component of its dermatology and wound care segment is the "Haidebao" brand, which utilizes calcium-based antimicrobial peptide (CAP) technology for skin repair and infection control. The "China Haidebao program" is a clinical research initiative sponsored by the company to support multicenter clinical trials and academic research for its Haidebao product line, including studies on atopic dermatitis. Grand Pharma is also a major player in nuclear medicine through its acquisition of Sirtex and its strategic partnership with Heidelberg Pharma for ADC development.